Printer Friendly

CAMBRIDGE BIOTECH LICENSES ITS STIMULON (TM) ADJUVANT TO UNIVAX BIOLOGICS FOR PRODUCTION OF POLYCLONAL ANTIBODY PRODUCTS

 WORCESTER, Mass., and Rockville, Md., April 22 /PRNewswire/ -- Cambridge Biotech Corporation (NASDAQ: CBCX) and Univax Biologics, Inc. (NASDAQ: UNVX) announced today that Univax has licensed Cambridge Biotech's patented Stimulon (TM) QS-21 adjuvant to produce polyclonal antibodies in plasma donor stimulation programs. Cambridge Biotech's adjuvant is a potent immune system stimulant that enhances immune response.
 This agreement between Cambridge Biotech and Univax involves the development of polyclonal antibody preparations that are designed to deliver specific antibodies directly into a patient's bloodstream. Univax will incorporate the QS-21 adjuvant in its proprietary vaccines used to stimulate plasma donors to produce antibodies. The resultant plasma will then be formulated into products to treat infectious diseases such as those associated with sepsis and cystic fibrosis.
 Univax has paid an initial license fee to Cambridge Biotech for rights to use the QS-21 adjuvant; it will make milestone payments as products move through clinical trials and will pay a royalty on sales once products are commercialized. Univax will be responsible for completing product development, conducting clinical trials, obtaining regulatory approvals, and marketing products resulting from use of the adjuvant. Cambridge Biotech will be responsible for manufacturing the adjuvant.
 This agreement is another step in Cambridge Biotech Corporation's business strategy, which includes a focus on developing strategic alliances with pharmaceutical partners in the vaccine and immunotherapeutic markets. Currently, the company has such alliances with SmithKline Beecham, Genentech, Pasteur Merieux Serums & Vaccins, and Virbac.
 Dr. Patrick J. Leonard, President and CEO of Cambridge Biotech, commented, "With this agreement our Stimulon adjuvant is now licensed for use in over 30 vaccines and immunotherapeutics that collectively represent a very large market potential in which Cambridge Biotech will ultimately participate. We are pleased to see Univax join our other strategic partners, and are confident that the agreement will be mutually beneficial and should lead to the introduction of more efficient and cost effective therapeutics."
 "What we like about the Stimulon QS-21 adjuvant is its potential, in combination with our proprietary vaccines, to produce very high levels of antibodies and to stimulate antibody production in large numbers of donors," said Thomas P. Stagnaro, Univax President and Chief Executive Officer. "We anticipate that Stimulon QS-21 will help us produce our products quickly and more cost-effectively because we should be able to make greater amounts of antibody with fewer donors."
 Cambridge Biotech Corporation is a leading diagnostics and therapeutics company involved in infectious diseases. The company is developing vaccines, adjuvants, and diagnostics for humans and animals.
 Univax Biologics, Inc., Rockville, Md., is a biopharmaceutical company devoted to exploiting the full potential of immunization technology for the prevention and treatment of infectious diseases. Univax's development-stage products utilize proprietary vaccines to stimulate active immunity as well as to produce polyclonal antibodies in healthy plasma donors. Founded in 1988, Univax has four products in human clinical trials and one product at the PLA stage.
 -0- 4/22/93
 /CONTACT: Peter P. Hartman, Vice President-Finance and Chief Financial Officer, Cambridge Biotech Corp., 508-797-5777; or Cabot Caskie, Vice President and Chief Financial Officer, Univax Biologics, Inc., 301/770-3099/
 (CBCX UNVX)


CO: Cambridge Biotech Corporation; Univax Biologics, Inc. ST: Massachusetts, Maryland IN: MTC SU:

DH -- NE005 -- 9185 04/22/93 08:39 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 22, 1993
Words:532
Previous Article:LOWEST INTEREST RATES IN 20 YEARS PROMPTS REFINANCE SURGE; COUNTRYWIDE FUNDING OFFERS REFINANCING TIPS
Next Article:AMERISCRIBE CORPORATION AGREES TO SETTLE LITIGATION
Topics:


Related Articles
CAMBRIDGE BIOTECH GRANTS SUBLICENSE TO GENENTECH FOR DEVELOPMENT OF AIDS VACCINE
CAMBRIDGE BIOTECH CORPORATION AND PASTEUR MERIEUX IN INFLUENZA VACCINE PARTNERSHIP
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
CAMBRIDGE BIOTECH CORPORATION AND GENENTECH, INC. AGREE TO VACCINE ALLIANCE
RESULTS OF HUMAN PHASE I TRIAL OF CAMBRIDGE BIOTECH CORPORATION'S STIMULON ADJUVANT REPORTED
CAMBRIDGE BIOTECH REPORTS 1992 RESULTS
CAMBRIDGE BIOTECH LICENSES ITS STIMULON ADJUVANT TO AMERICAN CYANAMID
CAMBRIDGE BIOTECH CORPORATION'S STIMULON ADJUVANT IN PHASE I TRIAL WITH GENENTECH HIV-1 VACCINE
CAMBRIDGE BIOTECH CORPORATION STIMULON(TM) ADJUVANT REPORTED TO ENHANCE TUMOR PROTECTION AND IMMUNE RESPONSE TO B16 MELANOMA VACCINES
Aquila Biopharmaceuticals Grants QS-21 License to Elan.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters